Literature DB >> 15365403

The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease.

Angela M Meyer1, Nizar N Ramzan, Edward V Loftus, Russell I Heigh, Jonathan A Leighton.   

Abstract

GOALS: We sought to determine the yield of stool analysis for bacterial culture, ova and parasites, and Clostridium difficile toxin in suspected relapses of inflammatory bowel disease (IBD).
BACKGROUND: The diagnostic yield of such stool studies has not been examined recently in the United States. STUDY: The medical records of consecutive IBD patients who underwent stool testing for relapses at our institution between July 1, 2000, and November 25, 2001, were abstracted for demographics, stool test results, recent antibiotic exposure, and hospitalization.
RESULTS: Fifty-four patients were evaluated during 62 relapses with 99 stool samples. Twelve stool tests were positive. C. difficile accounted for the majority of positive tests (10/12). Of these, 9 (90%) were associated with antibiotic use in the prior month versus 10 (22%) in the C. difficile-negative group (P < 0.001). Hospitalization, prednisone use, or sulfasalazine use did not differ significantly with C. difficile status. Eight C. difficile-positive patients improved clinically with targeted antibiotic therapy. Two bacterial cultures (4%) were positive for Campylobacter jejuni and Plesiomonas shigelloides.
CONCLUSION: Stool studies yielded a pathogen, mainly C. difficile, in 20% of the relapsing IBD patients. Antibiotic use was significantly associated with a positive C. difficile toxin. Toxin-positive patients improved clinically with targeted antibiotics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365403     DOI: 10.1097/01.mcg.0000139057.05297.d6

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  26 in total

Review 1.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 2.  Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective.

Authors:  Francesca Turroni; Marco Ventura; Ludovica F Buttó; Sabrina Duranti; Paul W O'Toole; Mary O'Connell Motherway; Douwe van Sinderen
Journal:  Cell Mol Life Sci       Date:  2013-03-21       Impact factor: 9.261

Review 3.  Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ?

Authors:  Peter Laszlo Lakatos; Simon Fischer; Laszlo Lakatos; Istvan Gal; Janos Papp
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

4.  The Toxin-Producing Pathobiont Klebsiella oxytoca Is Not Associated with Flares of Inflammatory Bowel Diseases.

Authors:  Ines Zollner-Schwetz; Kathrin A T Herzog; Gebhard Feierl; Eva Leitner; Georg Schneditz; Hanna Sprenger; Jürgen Prattes; Wolfgang Petritsch; Heimo Wenzl; Patrizia Kump; Gregor Gorkiewicz; Ellen Zechner; Christoph Högenauer
Journal:  Dig Dis Sci       Date:  2015-06-20       Impact factor: 3.199

5.  Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.

Authors:  Ethan Mezoff; Elizabeth A Mann; Kim Ward Hart; Christopher J Lindsell; Mitchell B Cohen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-04       Impact factor: 2.839

Review 6.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Clostridium Difficile Infection from a Surgical Perspective.

Authors:  Andreas M Kaiser; Rachel Hogen; Liliana Bordeianou; Karim Alavi; Paul E Wise; Ranjan Sudan
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

8.  Evolving concepts in Clostridium difficile colitis.

Authors:  Naomi G Diggs; Christina M Surawicz
Journal:  Curr Gastroenterol Rep       Date:  2009-10

9.  Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.

Authors:  Colleen R Kelly; Chioma Ihunnah; Monika Fischer; Alexander Khoruts; Christina Surawicz; Anita Afzali; Olga Aroniadis; Amy Barto; Thomas Borody; Andrea Giovanelli; Shelley Gordon; Michael Gluck; Elizabeth L Hohmann; Dina Kao; John Y Kao; Daniel P McQuillen; Mark Mellow; Kevin M Rank; Krishna Rao; Arnab Ray; Margot A Schwartz; Namita Singh; Neil Stollman; David L Suskind; Stephen M Vindigni; Ilan Youngster; Lawrence Brandt
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

10.  Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.

Authors:  Dejan Micic; Andres Yarur; Alex Gonsalves; Vijaya L Rao; Susan Broadaway; Russell Cohen; Sushila Dalal; John N Gaetano; Laura R Glick; Ayal Hirsch; Joel Pekow; Atsushi Sakuraba; Seth T Walk; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.